Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-01-25
2011-01-25
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07875629
ABSTRACT:
The invention provides novel quinolinone-carboxamide 5-HT4receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4receptor activity, and processes and intermediates useful for preparing such compounds.
REFERENCES:
patent: 4321378 (1982-03-01), Dostert et al.
patent: 4845092 (1989-07-01), Sanger et al.
patent: 4853394 (1989-08-01), King et al.
patent: 4937247 (1990-06-01), King
patent: 5017573 (1991-05-01), Kon et al.
patent: 5037844 (1991-08-01), Hamminga et al.
patent: 5047410 (1991-09-01), Donetti et al.
patent: 5223511 (1993-06-01), Turconi et al.
patent: 5248684 (1993-09-01), Suzuki et al.
patent: 5272154 (1993-12-01), Dixon et al.
patent: 5298510 (1994-03-01), Tyers
patent: 5319085 (1994-06-01), Suzuki et al.
patent: 5552398 (1996-09-01), King et al.
patent: 5561149 (1996-10-01), Azria et al.
patent: 5571820 (1996-11-01), Ohuchi et al.
patent: 5654320 (1997-08-01), Catlow et al.
patent: 5684003 (1997-11-01), Kikuchi et al.
patent: 5696129 (1997-12-01), King et al.
patent: 5733917 (1998-03-01), Ohuchi et al.
patent: 5741801 (1998-04-01), King et al.
patent: 5753673 (1998-05-01), Ohuchi et al.
patent: 5773436 (1998-06-01), Muller et al.
patent: 5864039 (1999-01-01), Kawakita et al.
patent: 5914405 (1999-06-01), Wilson
patent: 5945434 (1999-08-01), Suzuki et al.
patent: 6002009 (1999-12-01), Cereda et al.
patent: 6117882 (2000-09-01), Schaus et al.
patent: 6172062 (2001-01-01), Clark et al.
patent: 6197769 (2001-03-01), Alisi et al.
patent: 6281218 (2001-08-01), Cereda et al.
patent: 6294555 (2001-09-01), Kato et al.
patent: 6452013 (2002-09-01), Bosmans et al.
patent: 6544997 (2003-04-01), Bosmans et al.
patent: 6624162 (2003-09-01), Uchida et al.
patent: 6696468 (2004-02-01), Kato et al.
patent: 6979690 (2005-12-01), Gymer et al.
patent: 7317022 (2008-01-01), Gendron et al.
patent: 7329752 (2008-02-01), Long et al.
patent: 7351704 (2008-04-01), Marquess et al.
patent: 7375114 (2008-05-01), Marquess et al.
patent: 7396933 (2008-07-01), Choi et al.
patent: 7399862 (2008-07-01), Choi et al.
patent: 7419989 (2008-09-01), Fatheree et al.
patent: 2002/0173505 (2002-11-01), Skogvall
patent: 2004/0122043 (2004-06-01), Iguchi et al.
patent: 2004/0127514 (2004-07-01), Katsu et al.
patent: 2004/0266814 (2004-12-01), Noguchi et al.
patent: 2005/0148573 (2005-07-01), Katsu et al.
patent: 2005/0277671 (2005-12-01), Ando et al.
patent: 2005/0277672 (2005-12-01), Ando et al.
patent: 2005/0277673 (2005-12-01), Ando et al.
patent: 2008/0090811 (2008-04-01), Long et al.
patent: 2008/0132491 (2008-06-01), Fatheree et al.
patent: 2008/0146807 (2008-06-01), Marquess et al.
patent: 2008/0167295 (2008-07-01), Choi et al.
patent: 2008/0176895 (2008-07-01), Marquess et al.
patent: 0 309 423 (1989-03-01), None
patent: 0 623 621 (1994-11-01), None
patent: 2 154 605 (2001-04-01), None
patent: 01298271 (1999-12-01), None
patent: 04005289 (1992-01-01), None
patent: 08231544 (1996-09-01), None
patent: WO 93/03725 (1993-03-01), None
patent: WO 97/35860 (1997-10-01), None
patent: WO 99/20633 (1999-04-01), None
patent: WO 00/63215 (2000-10-01), None
patent: WO 01/25236 (2001-04-01), None
patent: WO 02/36113 (2002-05-01), None
patent: WO 2004/026868 (2004-04-01), None
patent: WO 2005/000837 (2005-01-01), None
patent: WO 2005/000838 (2005-01-01), None
patent: WO 2005/021539 (2005-03-01), None
patent: WO 2005/049608 (2005-06-01), None
patent: WO 2005/073222 (2005-08-01), None
patent: WO 2005/092882 (2005-10-01), None
Sugiuar et al., The Journal of neuroscience : the official journal of the Society for Neuroscience, (Oct. 27, 2004) vol. 24, No. 43, pp. 9521-9530.
Suzuki et al., Chemical & Pharmaceutical Bulletin (2001), 49(1), pp. 29-39.
U.S. Appl. No. 12/136,891, Choi et al.
Allegretti et al., “One-pot, new stereoselective synthesis ofendo-tropanamine”, Tetrahedron Letters 42, pp. 4257-4259 (2001).
Baxter et al., “Benzimidazolone derivatives act as 5-HT4receptor ligands in rat oesophagus”, European Journal of Pharmacology, 212, pp. 225-229 (1992).
Berdini et al., “A modified palladium catalysed reductive amination procedure”, Tetrahedron 58, pp. 5669-5674 (2002).
Bermudez et al., “5-Hydroxytryptamine (5-HT3) Receptor Antagonists. 1. Indazole and Indolizine-3-carboxylic Acid Derivatives”, J. Med. Chem., 33, pp. 1924-1929 (1990).
Blum et al., “Design and Synthesis of Novel Ligands for the 5-HT3and the 5-HT4Receptor”, Bioorganic & Medicinal Chemistry Letters, vol. 2, No. 5, pp. 461-466 (1992).
Curtet et al., “New Arylpiperazine Derivatives as Antagonists of the Human Cloned 5-HT4Receptor Isoforms”, J. Med. Chem., 43, pp. 3761-3769 (2000).
Dumuis et al., “Characterization of a novel 5-HT4receptor antagonist of the azabicycloalkyl benzimidazolone class: DAU 6285”, Naunyn-Schmiedeberg's Arch Pharmacol, 345, pp. 264-269 (1992).
Dumuis et al., “Azabicycloalkyl benzimidazolone derivatives as a novel class of potent agonists at the 5-HT4receptor positively coupled to adenylate cyclase in brain”, Naunyn-Schmiedeberg's Arch Pharmacol, 343, pp. 245-251 (1991).
Fake et al., “BRL 43694: A Potent and Novel 5-HT3Receptor Antagonist”, Br. J. Pharmacol., 91, 335P (1987).
Kaumann et al., “Indazole as an Indole Bioisostere:5-HT4Receptor Antagonism.”, Bioorganic & Medicinal Chemistry Letters, vol. 2, No. 5, pp. 419-420 (1992).
Langlois et al., “5-HT4Receptor Ligands: Applications and New Prospects”, J Med Chem, vol. 46, No. 3, pp. 319-344 (2003).
Lopez-Rodriguez et al., “3-D-QSAR/CoMFA and Recognition Models of Benzimidazole Derivatives at the 5-HT4Receptor”, Bioorganic & Medicinal Chemistry Letters, 11, pp. 2807-2811 (2001).
Lopez-Rodriguez et al., “Benzimidazole Derivates. Part 1: Synthesis and Structure-Activity Relationships of New Benzimidazole-4-carboxamides and Carboxylates as Potent and Selective 5-HT4Receptor Antagonists”, Bioorganic & Medicinal Chemistry, 7 , pp. 2271-2281 (1999).
Lopez-Rodriguez et al., “Benzimidazole Derivatives. 3. 3D-QSAR/CoMFA Model and Computational Simulation for the Recognition of 5-HT4Receptor Antagonists”, J. Med. Chem., 45, pp. 4806-4815 (2002).
Lopez-Rodriguez et al., “Benzimidazone derivatives 4. The recognition of the voluminous substituent attached to the basic amino group of 5-HT4receptor antagonists”, Journal of Computer-Aided Molecular Design, 17, pp. 515-524 (2003).
Lopez-Rodriguez et al., “Design and Synthesis of New Benzimidazole-Arylpiperazine Derivatives Acting as Mixed 5-HT1A/5-HT3Ligands”, Bioorganic & Medicinal Chemistry Letters, 13, pp. 3177-3180 (2003).
Lopez-Rodriguez et al., “Study of the bioactive conformation of novel 5-HT4receptor ligands: influence of an intramolecular hydrogen bond”, Tetrahedron, 57, pp. 6745-6749 (2001).
Schaus et al., “Synthesis and Structure-Activity Relationships of Potent and Orally Active 5-HT4Receptor Antagonists: Indazole and Benzimidazolone Derivatives”, J. Med. Chem., 41, pp. 1943-1955 (1998).
Suzuki et al., “Synthesis and Evaluation of Novel 2-Oxo-1,2-dihydro-3-quinolinecarboxamide Derivatives as Potent and Selective Serotonin 5-HT4Receptor Agonists”, Chem. Pharm. Bull., 49(1), pp. 29-39 (2001).
Suzuki et al., “A Practical Procedure for Preparation ofN-(endo-8-3-hydroxy)propyl-8-azabicyclo[3.2.1]oct-3-yl)-1-isopropyl-2-oxo-1,2-dihydro-3-quinoline-carboxamide (TS-951)”, Heterocycles, vol. 53, No. 11, pp. 2471-2485 (2000).
Suzuki et al., “Synthesis and Evaluation of Novel 2-Oxo-1,2-dihydro-3-quinolinecarboxamide Derivatives as Serotonin 5-HT4Receptor Agonists”, Chem. Pharm. Bull., 48(12), pp. 2003-2008 (2000).
Tapia et al., “2,3-Dihydro-2-oxo-1H-benzimidazole-1-carboxamides with Selective Affinity for the 5-HT4Receptor: Synthesis and Structure-Affinity and Structure-Activity Relationships of a Ne
Choi Seok-Ki
Fatheree Paul R.
Gendron Roland
Goldblum Adam A.
Jiang Lan
Hagenah Jeffrey A.
Rahmani Niloofar
Saxon Roberta P.
Seaman D. Margaret
Theravance Inc.
LandOfFree
Quinolinone compounds as 5-HT 4 receptor agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Quinolinone compounds as 5-HT 4 receptor agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinolinone compounds as 5-HT 4 receptor agonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2731386